PMID- 16979255
OWN - NLM
STAT- MEDLINE
DCOM- 20070425
LR  - 20221207
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 76
IP  - 1
DP  - 2007 Apr
TI  - Evaluation of the superiority of insulin glargine as basal insulin replacement by 
      continuous glucose monitoring system.
PG  - 30-6
AB  - To evaluate the superiority of insulin glargine as basal insulin replacement by 
      continuous glucose monitoring system (CGMS). Twenty-four patients with type 2 
      diabetes mellitus (T2DM) whose blood glucose was not well controlled with 
      sulphanylureas were enrolled. At first, they were treated with extended-release 
      glipizide (glucotrol XL) 5mg/d before breakfast for 2 weeks, then randomized to 
      combination treatment with glargine (16 patients) or NPH (8 patients) and treated 
      for 12 weeks. CGMS were carried in the second week after treatment with glucotrol 
      XL, and in the 12th week after combination treatment. The data of CGMS showed: 
      (1) When FPG were well controlled in both groups (glargine group versus NPH 
      group: 6.0+/-1.0 mmol/L versus 5.8+/-1.3 mmol/L), the blood glucose level at 3:00 
      a.m. (5.1+/-0.9 mmol/L versus 4.2+/-0.8 mmol/L) were higher (P<0.05), TPG< or 
      =3.0 mmol/L at night were lower (2.56+/-1.79 versus 5.88+/-1.96), and the rate of 
      nocturnal hypoglycemia (1/16 versus 4/8) were less (P=0.028) in glargine group 
      than those in NPH group. (2) CGMS showed that the daily blood glucose profile 
      excursion were more smoother in glargine group than those in NPH group. In 
      conclusion, it was confirmed with CGMS that compared with traditionally basal 
      insulin replacement with NPH, the combination treatment with glargine injection 
      at bedtime may be predominant for stabilizing the daily blood glucose profile 
      excursion and decreasing the nocturnal hypoglycemia events incidence. So glargine 
      may be a more ideal basal insulin replacement than NPH.
FAU - Wang, Xian Ling
AU  - Wang XL
AD  - Department of Endocrinology, Chinese PLA General Hospital, Fu Xing Road 28, 
      Beijing 100853, China.
FAU - Lu, Ju Ming
AU  - Lu JM
FAU - Pan, Chang Yu
AU  - Pan CY
FAU - Mu, Yi Ming
AU  - Mu YM
FAU - Dou, Jing Tao
AU  - Dou JT
FAU - Ba, Jian Ming
AU  - Ba JM
FAU - Wang, Xuemin
AU  - Wang X
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060915
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 53027-39-7 (Insulin, Isophane)
RN  - X7WDT95N5C (Glipizide)
SB  - IM
MH  - Blood Glucose/*analysis/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Evaluation Studies as Topic
MH  - Fasting
MH  - Female
MH  - Glipizide/administration & dosage/therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Insulin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Isophane/administration & dosage/therapeutic use
MH  - Insulin, Long-Acting
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/instrumentation/methods
MH  - Treatment Outcome
EDAT- 2006/09/19 09:00
MHDA- 2007/04/26 09:00
CRDT- 2006/09/19 09:00
PHST- 2006/05/25 00:00 [received]
PHST- 2006/08/09 00:00 [accepted]
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2007/04/26 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
AID - S0168-8227(06)00352-4 [pii]
AID - 10.1016/j.diabres.2006.08.005 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2007 Apr;76(1):30-6. doi: 10.1016/j.diabres.2006.08.005. 
      Epub 2006 Sep 15.